Study to Test TEV-50717 in Relieving Abnormal Involuntary Movements in Cerebral Palsy
- Study Title
- A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy
- Teva Identifier
- TV50717-CNS-30081 | 2019-001807-19
- ClinicalTrials.gov Identifier
- NCT04200352
- Study Status
- Terminated
- Trial Condition(s)
- Cerebral Palsy, Dyskinetic
- Interventions
- Drug: TEV-50717
- EudraCT Number
- 2019-001807-19
- Study Description
- Study TV50717-CNS-30081 is a 55-week study in which patients who have successfully completed the parent study (Study TV50717-CNS-30080) may be eligible to enroll in this study. The primary objective of this study is to evaluate the safety and tolerability of long-term therapy with TEV-50717 in children and adolescents with DCP. The secondary objective of this study is to evaluate the efficacy of long-term therapy with TEV-50717 in reducing the severity of DCP.
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Child, Adult
- Age Range
- 6 Years to 18 Years
- Trial Duration
- February 4, 2020 - August 19, 2023
- Phase
- Phase 3
Additional info
Study Type
InterventionalLocation - Where to Participate
You may contact 1-888-483-8279 or email USMedInfo@tevapharm.com to obtain more information about study locations.
